The division is nationally distinguished for its design and conduct of NIH-funded multi-center clinical trials involving childhood cancer, sickle cell disease, and hemorrhagic disorders. Our faculty are actively involved in clinical research projects and laboratory research.
Each Hematology-Oncology faculty physician participates in joint clinical research projects, particularly involving the Children’s Oncology Group (COG), for which Naomi Winick, M.D., is the center’s Principal Investigator. All faculty members in the division are members of COG, an NIH-funded multi-institutional consortium of cancer research centers.
The division conducts a number of in-house therapeutic studies for children with cancer, including innovative research programs in acute lymphoblastic leukemia (ALL) and Phase I and II trials for patients with advanced malignancies of various types. Other institutional research studies focus on genetic alterations in cancer, late effects in cancer survivors, and supportive care of children with cancer.
Faculty and fellows are involved in numerous clinical studies involving hematology patients (sickle cell disease, hereditary spherocytosis, thrombosis, and immune thrombocytopenia (ITP)), and many are multi-center trials supported by the NIH. The program was funded by the National Heart, Lung and Blood Institute (NHLBI) as one of 10 comprehensive sickle cell centers to participate in a clinical trials consortium, and Children’s Medical Center is currently one of a select group of children’s hospitals nationally involved in a Sickle Cell Disease Basic and Translational Research Program initiated in April 2008.
The division also is a member of the NHLBI-supported Transfusion Medicine-Hemostasis Clinical Trials Network, in which several of its faculty are involved in studies involving platelet transfusion dosing, ITP management, and hemophilia treatment.
In addition to these multi-center studies, more than a dozen local investigator-initiated research projects in hematology are in progress.